Princeton Global Asset Management’s Viking Therapeutics VKTX Stock Holding History

Princeton Global Asset Management’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-2,500	Closed	-$8K	–	595
2022 Q1	$8K	Hold	2,500	–	–	﹤0.01%	472
2021 Q4	$12K	Hold	2,500	–	–	﹤0.01%	395
2021 Q3	$16K	Hold	2,500	–	–	﹤0.01%	367
2021 Q2	$15K	Hold	2,500	–	–	﹤0.01%	379
2021 Q1	$16K	Hold	2,500	–	–	0.01%	346
2020 Q4	$14K	Buy	+2,500	New	+$15.1K	﹤0.01%	366

Other funds holding VKTX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.47B AUM 86.42% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

LCM

Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

SCM

Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

Princeton Global Asset Management's VKTX Position: Q2 2022 in Review

Princeton Global Asset Management sold out of Viking Therapeutics (VKTX) in Q2 2022, closing a stake of 2,500 shares — an estimated $8K sold.

Princeton Global Asset Management first reported a position in VKTX in Q4 2020 and held it in 6 quarters. The position peaked at $16K in Q3 2021. 114 funds tracked by Wall St. Rank hold VKTX as of Q2 2022.

Princeton Global Asset Management reported no remaining Viking Therapeutics position as of Q2 2022 after selling out during the quarter.
Princeton Global Asset Management sold 2,500 Viking Therapeutics shares in Q2 2022, an estimated $8K.
Princeton Global Asset Management first reported a position in Viking Therapeutics in Q4 2020 and held it in 6 quarters.
Princeton Global Asset Management's Viking Therapeutics position peaked at $16K in Q3 2021.
114 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2022.

Based on Princeton Global Asset Management's 13F filing for Q2 2022, filed 4 Aug 2022.